Janssen Entered into a Worldwide Collaboration and License Agreement with Cellular Biomedicine to Develop and Commercialize CAR-T Therapies for Non-Hodgkin Lymphoma
Shots:
- CBMG will receive a $245M up front & additional fees upon achievement of clinical development, regulatory & sales milestones along with royalties excl. Greater China. The transaction is expected to close in Q2’23
- Janssen to get an exclusive license to develop & commercialize C-CAR039 (anti-CD19 & CD20 bi-specific CAR-T therapy) & C-CAR066 (anti-CD20 CAR-T) in geographic territories outside of China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the China territory
- The agreement deepens Janssen’s leadership in oncology & hematology and accelerates commitment to deliver cell therapies. The P-Ib study of C-CAR039 in the US is underway for r/r DLBCL while the P-Ib study of C-CAR066 is expected to initiate in H2’23
Ref: PR Newswire | Image: Janssen
Related News:- Janssen Reports P-II Study (SunRISe-1) Results of TAR-200 for the Treatment of Patients with BCG-Unresponsive HR-NMIBC CIS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
